Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

Kelly, Gemma L; Grabow, Stephanie; Glaser, Stefan P; Fitzsimmons, Leah; Aubrey, Brandon J; Okamoto, Toru; Valente, Liz J; Robati, Mikara; Tai, Lin; Fairlie, W Douglas; Lee, Erinna F; Lindstrom, Mikael S; Wiman, Klas G; Huang, David C S; Bouillet, Philippe; Rowe, Martin; Rickinson, Alan B; Herold, Marco J; Strasser, Andreas

DOI: 10.1101/gad.232009.113

License: None: All rights reserved

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (©)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 05. Aug. 2019
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

Gemma L. Kelly, Stephanie Grabow, Stefan P. Glaser, et al.

*Genes Dev.* 2014 28: 58-70
Access the most recent version at doi:10.1101/gad.232009.113

<table>
<thead>
<tr>
<th>Supplemental Material</th>
<th><a href="http://genesdev.cshlp.org/content/suppl/2014/01/06/28.1.58.DC1.html">http://genesdev.cshlp.org/content/suppl/2014/01/06/28.1.58.DC1.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 60 articles, 27 of which can be accessed free at: <a href="http://genesdev.cshlp.org/content/28/1/58.full.html#ref-list-1">http://genesdev.cshlp.org/content/28/1/58.full.html#ref-list-1</a></td>
</tr>
<tr>
<td>Creative Commons License</td>
<td>This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <a href="http://genesdev.cshlp.org/site/misc/terms.xhtml">http://genesdev.cshlp.org/site/misc/terms.xhtml</a>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at <a href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</a>.</td>
</tr>
<tr>
<td>Email Alerting Service</td>
<td>Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.</td>
</tr>
</tbody>
</table>
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

Gemma L. Kelly,1,2,3 Stephanie Grabow,1,3 Stefan P. Glaser,1,3 Leah Fitzsimmons,2 Brandon J. Aubrey,1,3 Toru Okamoto,1,3,6 Liz J. Valente,1,3 Mikara Robati,1 Lin Tai,1 W. Douglas Fairlie,1,3 Erinnna F. Lee,1,3 Mikael S. Lindstrom,4 Klas G. Wiman,4 David C.S. Huang,1,3 Philippe Bouillet,1,3 Martin Rowe,2 Alan B. Rickinson,2 Marco J. Herold,1,3,5 and Andreas Strasser1,3,5,7

1The Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia; 2School of Cancer Sciences, University of Birmingham College of Medical and Dental Sciences, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom; 3Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3050 Australia; 4Department of Oncology–Pathology, Karolinska Institute, Cancer Center Karolinska (CCK), SE-171 76 Stockholm, Sweden

The transcriptional regulator c-MYC is abnormally overexpressed in many human cancers. Evasion from apoptosis is critical for cancer development, particularly c-MYC-driven cancers. We explored which anti-apoptotic BCL-2 family member (expressed under endogenous regulation) is essential to sustain c-MYC-driven lymphoma growth to reveal which should be targeted for cancer therapy. Remarkably, inducible Cre-mediated deletion of even a single Mcl-1 allele substantially impaired the growth of c-MYC-driven mouse lymphomas. Mutations in p53 could diminish but not obviate the dependency of c-MYC-driven mouse lymphomas on MCL-1. Importantly, targeting of MCL-1 killed c-MYC-driven human Burkitt lymphoma cells, even those bearing mutations in p53. Given that loss of one allele of Mcl-1 is well tolerated in healthy tissues, our results suggest that therapeutic targeting of MCL-1 would be an attractive therapeutic strategy for MYC-driven cancers.

[Keywords: cancer; apoptosis; MCL-1; p53; BCL-2; MYC]

Supplemental material is available for this article.

Received October 1, 2013; revised version accepted November 19, 2013.

The c-MYC transcription factor regulates ~10,000 genes, including many that control cell growth and division [Dang 1999]. Deregulated c-MYC expression is detected in up to 70% of human cancers, including lymphomas and leukemias (Boxer and Dang 2001; Sanchez-Beato et al. 2003). Much of what we know about c-MYC-driven tumorigenesis has emerged from studies using Em-Myc transgenic mice, in which the c-Myc transgene is subjugated to the immunoglobulin (Ig) heavy chain gene enhancer (Em), mimicking the consequences of the c-MYC/IGH or c-MYC/IGL chromosomal translocations that drive human Burkitt lymphoma [Adams et al. 1985]. The Em-Myc mice exhibit a preleukemic expansion of pre-B cells that precedes the outgrowth of clonal slg Ig− pre-B-cell or slg Ig+ B-cell lymphomas arising with a median latency of ~110 d [Adams et al. 1985; Langdon et al. 1986].

Evasion from cell death is a hallmark of cancer, particularly those driven by c-MYC [Hanahan and Weinberg 2011; Kelly and Strasser 2011]. Deregulated c-MYC expression enhances cell death under unfavorable growth conditions, such as limited availability of growth factors, through the intrinsic apoptotic pathway that is regulated by interactions of proteins belonging to three functionally distinct subgroups of the BCL-2 family [Youle and Strasser 2008]. Following apoptotic stimuli, the proapoptotic BH3-only proteins (e.g., BIM and PUMA) become transcriptionally and/or post-transcriptionally up-regulated. For example, in response to DNA damage or oncogenic stress, the tumor suppressor p53 directly transcriptionally activates PUMA and NOXA to cause cell death [Jeffers et al. 2003; Villunger et al. 2003]. The BH3-only proteins directly or indirectly activate BAX/BAK, the executioners of apoptosis, which permeabilize the outer
mitochondrial membrane and thereby unleash the downstream caspase cascade for cellular demolition (Merino et al. 2009; Llambi et al. 2011).

Apoptotic blocks, such as overexpression of prosurvival BCL-2-like proteins (Strasser et al. 1990; Swanson et al. 2004) or loss of proapoptotic BIM or PUMA (Egle et al. 2004; Hemann et al. 2004; Michalak et al. 2009), accelerate c-MYC-driven lymphogenesis. Interestingly, mutations that deregulate the intrinsic apoptotic pathway, including amplifications of the genomic regions encoding MCL-1 and BCL-X (Berekhkim et al. 2010), are detected in human tumors and are often associated with poor chemotherapy responses (Khaw et al. 2011). Burkitt lymphoma is associated with frequent loss of BIM and/or PUMA expression, in part due to gene hypermethylation [Mestre-Escorihuela et al. 2007; Garrison et al. 2008; Richter-Larrea et al. 2010; Giulino-Roth et al. 2012]. Moreover, many Burkitt lymphomas contain defects in the p53 tumor suppressor pathway, particularly mutations in p53 itself [Farrell et al. 1991; Bhatia et al. 1992] but also overexpression of the ubiquitin ligase HDI2 (called MDM2 in mice) or loss of the p14/ARF locus [Lindstrom et al. 2001].

Although overexpression of prosurvival BCL-2 family members accelerates c-MYC-induced lymphogenesis, it is unclear whether the sustained survival and growth of c-MYC-driven lymphomas depends on the expression of these proteins under endogenous regulation. This remains an important question because knowledge of which prosurvival protein is essential for the sustained growth of a particular cancer will pinpoint the family member that should be targeted by the emerging BH3 mimetic drugs (Lessene et al. 2008). Using innovative gene targeting and drug-mimicking tools, we show for the first time that MCL-1 targeting kills c-MYC-driven mouse and human lymphoma cells even when p53 is mutated. This is remarkable given that we found that p53 does affect the dependency of these lymphoma cells on MCL-1 and suggest that therapeutic targeting of MCL-1 may be a promising strategy for cancer therapy.

**Results**

**Experimental strategy to determine which anti-apoptotic BCL-2 family member is essential for the sustained survival and expansion of MYC-driven lymphomas**

To examine the roles of BCL-XL and MCL-1 expression under endogenous control in the sustained growth of \( E\mu\)-Myc lymphomas, we generated mice in which we could genetically delete Mcl-1 or Bcl-x at will exclusively within c-MYC-driven lymphoma cells. Specifically, we produced \( E\mu\)-Myc transgenic mice that express a tamoxifen-regulated Cre recombinase-estrogen receptor fusion protein from the ubiquitously expressed Rosa26 locus (Rosa26-CreERT2 mice; Seibler et al. 2003) and bear loxP targeted [floxed, denoted \( fl\)] alleles of the prosurvival gene Bcl-x [Wagner et al. 2000] or Mcl-1 [Vikstrom et al. 2010] (Supplemental Fig. 1). As expected, the progeny with all three genetic alterations developed lymphomas with the same latency as standard \( E\mu\)-Myc mice [Supplemental Fig. 2A] because they expressed normal levels of BCL-XL or MCL-1. The lymphoma cells were transplanted into C57BL/6-Ly5.1+ recipients, which were treated with tamoxifen to activate the Cre-ERT2 recombinase, leading to deletion of Bcl-x\(^{fl}\) or Mcl-1\(^{fl}\) alleles exclusively within the malignant cells [Supplemental Fig. 1]. Selected primary lymphomas were infected with an Ub-GFP-Luciferase lentivirus to facilitate monitoring lymphoma progression/regression following Bcl-x or Mcl-1 deletion by imaging for bioluminescence in C57BL/6-albino recipient mice [Supplemental Fig. 1]. In mice transplanted with \( E\mu\)-Myc;CreERT2 lymphoma cells lacking any floxed allele (for simplicity, hereafter termed “control”), tumor expansion did not differ significantly between untreated and tamoxifen-treated recipients \([P = 0.06]\) [Supplemental Fig. 2B]. This shows that CreERT2 activation per se does not impair the growth of \( E\mu\)-Myc lymphomas.

**Homozygous loss of Bcl-x only slightly impairs the sustained growth of \( E\mu\)-Myc lymphomas**

Since endogenous BCL-XL is necessary for \( E\mu\)-Myc-induced lymphoma development [Kelly et al. 2011], we predicted that it might also be essential for the sustained expansion of such malignant lymphomas. To examine this, primary lymphomas from nine \( E\mu\)-Myc;CreERT2;Bcl-x\(^{fl}\) and seven control mice were transplanted into C57BL/6-Ly5.1+ recipient mice and cohorts treated with tamoxifen. Homozygous Bcl-x loss resulted in only a modest delay in tumor expansion and slightly prolonged survival of the mice [median survival 25 d for \( E\mu\)-Myc;CreERT2;Bcl-x\(^{fl}\) vs. 19 d for the controls; \([*] P = 0.0367]\) [Fig. 1A]. Following homozygous Bcl-x deletion, only 4% of the recipient mice [three from 73] showed complete lymphoma regression, which is comparable with the 3% of the tamoxifen-treated mice [one from 32] bearing control tumors.

This result was confirmed by in vivo lymphoma bioluminescence imaging [Fig. 1B]. As early as 7 d after tumor transplant, the recipients displayed a significant lymphoma burden \([\approx 1 \times 10^7 \text{ photon flux per second}]\). These lymphomas continued to grow following tamoxifen treatment to delete both Bcl-x alleles and overwhelmed the recipients only shortly after the untreated mice had succumbed to the same lymphomas that retained Bcl-x. Efficient deletion of the Bcl-x alleles and loss of the BCL-XL protein were confirmed by quantitative RT–PCR [qRT–PCR] and Western blot analyses in paired tamoxifen-treated and untreated lymphomas taken from mice transplanted with \( E\mu\)-Myc;CreERT2;Bcl-x\(^{fl}\) lymphomas [Supplemental Fig. 3]. These data reveal that malignant \( E\mu\)-Myc lymphomas can continue to grow without endogenous BCL-XL expression.

**Loss of Mcl-1 substantially impairs the sustained growth of \( E\mu\)-Myc lymphomas**

In parallel experiments, we investigated whether MCL-1 was essential for the sustained growth of \( E\mu\)-Myc lymphomas. Cohorts of C57BL/6-Ly5.1+ mice were transplanted with independent primary lymphomas from six
**Eμ-Myc;CreERT2;Mcl-1^fl/fl** and seven control mice, and their survival was compared following tamoxifen treatment (Fig. 2). Strikingly, in 30% of the recipients, homozygous deletion of Mcl-1 provoked complete lymphoma regression and extended survival (>180 d post-transplant) [Fig. 2A]. The dramatic tumor regression was confirmed by bioluminescence imaging of lymphomas transplanted into C57BL/6-albino recipient mice (Fig. 2B). Importantly, even the tamoxifen-treated recipients that relapsed exhibited substantially extended survival compared with those bearing control lymphomas (median survival 35 d for mice bearing **Eμ-Myc;CreERT2;Mcl-1^fl/fl** lymphomas vs. 19 d for those bearing control lymphomas; [****] \(P < 0.0001\)).

Remarkably, even heterozygous Mcl-1^fl^ loss substantially impaired sustained lymphoma growth: 20% of recipient mice bearing **Eμ-Myc;CreERT2;Mcl-1^fl/+** lymphomas showed prolonged survival after tamoxifen treatment (median survival was 23 d for relapsing lymphomas vs. 19 d for control mice; [****] \(P < 0.0001\)) (Fig. 2A).

These results demonstrate that the level of MCL-1 is highly critical for the sustained survival and expansion of MYC-driven lymphomas. This conclusion was strengthened by further analysis of the relapsing tamoxifen-treated lymphomas. The conditional allele of Mcl-1 carries a human (hu) CD4 reporter gene, which is expressed following Mcl-1^fl^ recombination, thus permitting single-cell analysis of the recombination efficiency (Vikstrom et al. 2010; Glaser et al. 2012). Strikingly, ~60% of **Eμ-Myc;CreERT2;Mcl-1^fl/+** and 40% of **Eμ-Myc;CreERT2;Mcl-1^fl/fl** lymphomas that relapsed following tamoxifen treatment had escaped deletion of their conditional Mcl-1 alleles mostly because they had undergone selection for loss of CreERT2 expression (Fig. 3A,B). Western blot analysis of these tamoxifen-treated tumors confirmed that MCL-1 protein expression was not reduced (Fig. 3B). In addition, the minority of **Eμ-Myc;CreERT2;Mcl-1^fl/fl** lymphomas that did relapse as huCD4-positive following tamoxifen treatment had only recombined one allele of Mcl-1 and continued to express MCL-1 protein (Fig. 3C,D).

By inference, the survival curves described earlier grossly underestimate the role that MCL-1 plays in the sustained growth of **Eμ-Myc** lymphomas. Indeed when animals that succumbed to relapsed lymphomas that had selected

---

**Figure 1.** Homozygous loss of Bcl-x has only a minor impact on the growth of Eμ-Myc lymphomas. (A) Survival curves of C57BL/6-Ly5.1^+^ recipient mice transplanted with **Eμ-Myc;CreERT2;Bcl-x^fl/fl** (green line) or control (**Eμ-Myc;CreERT2**; black line) lymphoma cells and treated with tamoxifen to inactivate Bcl-x where applicable. (n) Total number of recipient mice analyzed; (N) number of independent lymphomas tested. Homozygous deletion of Bcl-x resulted in a small but significant delay in tumor growth. (*) \(P = 0.0367\). For the mice transplanted with the control **Eμ-Myc;CreERT2** lymphomas, 3% regressed, and the overall median survival was 19 d. For the mice transplanted with the **Eμ-Myc;CreERT2;Bcl-x^fl/fl** lymphomas, 4% regressed, and the overall median survival was 25 d. (B) Bioluminescence imaging of the tumor burden in C57BL/6-albino recipient mice injected with primary **Eμ-Myc;CreERT2;Bcl-x^fl/fl** lymphoma cells that had been transduced with a lentiviral vector coexpressing GFP and luciferase. At 7 d post-transplant, a cohort of these mice was treated with tamoxifen. Mice were subsequently imaged for bioluminescence to monitor lymphoma burden every 3–4 d by measuring the total photon flux per second emitted from a region of interest (ROI) drawn around the whole mouse. See also Supplemental Figure 3.
against loss of Mcl-1 homozygous lymphomas were removed from the analysis (and those lymphomas that had mutated p53 alleles were also removed from the survival curves) [Fig. 5A; see below], nearly 100% of animals survived lymphoma-free long-term (>180 d post-transplant) [Fig. 3E]. These findings reveal that even heterozygous Mcl-1 loss is highly detrimental for the sustained in vivo growth of malignant Eμ-Myc lymphomas, indicating that relatively weak targeting of MCL-1 might have therapeutic benefits in MYC-driven cancers.

**The sustained growth of human Burkitt lymphoma cells depends on the expression of MCL-1**

We sought to translate these findings into the human disease setting. Western blot analysis of Burkitt lymphoma cell lines revealed that all expressed MCL-1 with heterogeneous expression of BCL-XL and, as previously reported [Henderson et al. 1991] little to no BCL-2 (Fig. 4A). As a control for the BCL-2 antibody, we showed that the X50-7 and Awia-tr lymphoblastoid cell lines expressed high levels of this prosurvival protein [Fig. 4A], as reported [Henderson et al. 1991].

To examine the impact of targeting BCL-2 prosurvival proteins on Burkitt lymphoma growth, we developed a novel assay based on doxycycline (dox)-inducible expression [from a lentiviral vector] of genetically engineered variants of the BH3-only protein BIM S with select binding specificities for distinct BCL-2 prosurvival proteins [Fig. 4B; Chen et al. 2005; Lee et al. 2008]. These polypeptides have a mechanism of action similar to that of BH3 mimetic drugs; i.e., they antagonize BCL-2 prosurvival protein function by engaging a hydrophobic ligand-binding groove on their surface [Lee et al. 2007, 2008; Souers et al. 2013]. The wild-type BIM S, which binds with high affinity to all BCL-2 prosurvival proteins, served as a positive control for the integrity of the intrinsic apoptotic pathway. Mutant BIM S4E, which does not bind to any BCL-2 prosurvival family member, thus served as a negative control. L62A/F69A mutant BIM S2A preferentially binds MCL-1, and BIM S2BAD binds to BCL-2, BCL-XL, and BCL-W. Western blotting verified inducible expression of all BIM S variants in Rael-BL [Fig. 4C] and other Burkitt lymphoma cell lines [Supplemental Fig. 4A]. All Burkitt lymphoma cell lines tested were highly sensitive to the expression of wild-type BIM S, demonstrating that they had an intact intrinsic apoptotic pathway. Conversely, as expected, these cells were not affected by BIM S4E [representative FACS plots are shown in Supplemental Fig. 4B].

Figure 2. Loss of Mcl-1, even loss of a single allele, greatly impairs the sustained growth of Eμ-Myc lymphomas within the whole animal. (A) Survival curves of C57BL/6-Ly5.1+ recipient mice transplanted with Eμ-Myc;CreERT2, Mcl-1+/− [red line], Eμ-Myc;CreERT2, Mcl-1−/− [blue line], or control [Eμ-Myc;CreERT2, black line] lymphoma cells and treated with tamoxifen to inactivate Mcl-1 where applicable. (n) Total number of recipient mice analyzed; (N) number of independent lymphomas tested. Heterozygous and homozygous deletion of Mcl-1 significantly delayed lymphoma growth. (****) *P < 0.0001. For the mice transplanted with the control Eμ-Myc;CreERT2 lymphomas, 3% regressed, and the overall median survival was 19 d. For the mice transplanted with the Eμ-Myc;CreERT2, Mcl-1−/− lymphomas, 20% regressed, and the overall median survival was 23 d. For the mice transplanted with the Eμ-Myc;CreERT2, Mcl-1−/− lymphomas, 30% regressed, and the overall median survival was 35 d. (B) Bioluminescence imaging of the tumor burden in C57BL/6-albino recipient mice injected with primary Eμ-Myc; CreERT2, Mcl-1−/− lymphoma cells. At 10 d post-transplant, a cohort of these mice was treated with tamoxifen. These mice were subsequently imaged for bioluminescence.
Figure 3. Most Eμ-Myc lymphomas that relapse following tamoxifen treatment have escaped Mcl-1\textsuperscript{fl} allele recombination. (A) FACS analysis to detect expression of huCD4 [reporter for Mcl-1\textsuperscript{fl} recombination] on the surface of two representative Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} and Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} lymphomas that had relapsed in recipient mice after tamoxifen treatment (transplanted lymphoma cells stained positive for Ly5.2). Approximately 60% of the relapsed Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} and 40% of the relapsed Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} lymphoma cells had escaped Mcl-1\textsuperscript{fl} allele recombination and, as such, were huCD4-negative [like the sample at the left of each pair], whereas ~40% of the relapsed Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} and 60% of the relapsed Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} lymphomas had efficiently recombined at least one Mcl-1\textsuperscript{fl} allele, as reflected by staining positive for huCD4 (like the sample at the right of each pair). (B) Immunoblotting to detect MCL-1 and CreERT2 protein expression [probing for Actin was used as a loading control] in extracts from the spleens, lymph nodes, or thymuses of sick mice that had been transplanted with Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} or Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} lymphomas. Three independent, paired control, and tamoxifen-treated tumors of each genotype were analyzed (note that one of the Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} tumors [#3] examined never relapsed after tamoxifen treatment). Mcl-1 knockout (KO) mouse embryonic fibroblasts (MEFs) were used as a control to confirm the specificity of the MCL-1 antibody (neg control). (C) DNA PCR analysis of recombined Mcl-1\textsuperscript{fl} and unrecombined (intact) floxed alleles in Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} lymphomas that relapsed following tamoxifen treatment. (D) Immunoblotting to detect MCL-1 and CreERT2 protein expression in extracts from the spleens, lymph nodes, or thymuses of sick mice that had been transplanted with Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} or Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} lymphomas. Three independent, paired control, and tamoxifen-treated tumors of each genotype were analyzed [note that one of the Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} tumors [#3] examined never relapsed after tamoxifen treatment]. Mcl-1 knockout (KO) mouse embryonic fibroblasts (MEFs) were used as a control (neg control) to confirm the specificity of the MCL-1 antibody. (E) Survival curves of C57BL/6-Ly5.1\textsuperscript{+} recipient mice transplanted with Eμ-Myc;CreERT2 lymphomas that had wild-type p53 genes following tamoxifen treatment excluding those lymphomas that escaped Cre-mediated deletion of one or both Mcl-1\textsuperscript{fl} alleles. C57BL/6-Ly5.1\textsuperscript{+} recipient mice transplanted with control [Eμ-Myc;CreERT2; black line] lymphoma cells and treated with tamoxifen are shown for comparison. (n) Total number of recipient mice analyzed; (N) number of independent lymphomas tested. Efficient heterozygous and homozygous deletion of Mcl-1 significantly delayed lymphoma growth. (****) P < 0.0001. For the mice transplanted with the control Eμ-Myc;CreERT2 lymphomas, 3% regressed, and the overall median survival was 19 d. For the mice transplanted with the Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/+} lymphomas, 94% regressed, and the overall median survival was >180 d. For the mice transplanted with the Eμ-Myc;CreERT2;Mcl-1\textsuperscript{fl/fl} lymphomas, 100% regressed, and the overall median survival was >180 d.
Notably, all Burkitt lymphoma cells were sensitive to BIMS2A, indicating a dependency on MCL-1 (Fig. 4D; Supplemental Fig. 4D). Ramos-BL, BL31, and Sav-BL were also sensitive to BIMSBAD (and, accordingly, also to treatment with ABT-737, which targets BCL-XL, BCL-2, and BCL-W), albeit for Ramos-BL and BL31, significantly less than to BIMS2A, indicating only a partial dependency on BCL-XL (Fig. 4D; Supplemental Fig. 4C,D). Kinetic binding analyses using the Biacore confirmed that the more potent killing activity of BIMS2A versus BIMSBAD on most cell lines reflected the dependence of these cells on MCL-1 rather than a greater capacity of BIMS2A to engage MCL-1 compared with the ability of BIMSBAD to bind BCL-XL. Indeed these Biacore binding assays showed that the affinity of the BAD-BH3 is actually ~20-fold higher for BCL-XL (similar to that of wild-type BIMSB BH3) than the affinity of BIMS2A for MCL-1 due to a significantly faster dissociation rate in the MCL-1 interaction.
[Supplemental Fig. 4E]. Collectively, these results show that the sustained survival and growth of Burkitt lymphoma cells is dependent on MCL-1 either alone or with a contribution by BCL-X\textsubscript{L}.

**Mutations in p53 reduce but do not ablate the dependency of c-MYC-driven mouse and human lymphomas on MCL-1**

Although most transplanted \(\text{E\textsubscript{µ}-Myc}\) mouse lymphomas (14 from 23 analyzed) could not continue to grow following heterozygous recombination of \(\text{Mcl-1}\textsubscript{fl/fl}\), a minority of relapsing lymphomas (nine from 23 analyzed) did display heterozygous \(\text{Mcl-1}\textsubscript{fl/fl}\) allele deletion, as demonstrated by huCD4 immunostaining [Fig. 3A]. We were interested to understand why these lymphoma cells were less dependent on MCL-1 for their growth, since such insights will be critical for predicting the therapeutic response of c-MYC-driven lymphomas and other cancers to MCL-1 antagonists. Interestingly, we noticed that most lymphomas capable of growth following transplantation and heterogeneous \(\text{Mcl-1}\textsubscript{fl/fl}\) loss (seven of nine identified) displayed dramatically increased expression of the tumor suppressor p53 [Figs. 3D, 5A], a hallmark of p53 gene mutations. DNA sequence analysis confirmed the presence of mutations affecting known “hot spot” residues [Freed-Pastor and Prives 2012] within the DNA-binding domain of p53 in the primary lymphomas capable of growing following transplantation and heterozygous deletion of \(\text{Mcl-1}\) [Figs. 3D, 5B]. This suggests that the presence of existing mutations in the p53 gene decreased the dependency of these tumor cells on MCL-1. An additional relapsed lymphoma of genotype \(\text{E\textsubscript{µ}-Myc; CreERT2;Mcl-1}\textsubscript{fl/fl}\) (#6) showed evidence of p53 pathway mutation (increased p19ARF protein expression) upon tamoxifen treatment [increasing the frequency to eight of nine lymphomas showing perturbation of the p53 pathway] [Fig. 3D]. As a control, we sequenced the p53 gene in seven of the 14 lymphomas that expressed physiological (i.e., very low/barely detectable in the absence of genotoxic stress) levels of p53 [indicative of wild-type nonmutated p53 genes] and were not capable of growing following heterozygous loss of \(\text{Mcl-1}\) and confirmed that their p53 genes were wild type. This highlights a novel and highly specific interplay between malignant cell survival dependency on MCL-1 and the p53 tumor suppressor pathway. Importantly, a lymphoma of genotype \(\text{E\textsubscript{µ}-Myc; CreERT2;Mcl-1}\textsubscript{fl/fl}\) (#3) carrying the p53 mutation that introduced a stop codon almost always regressed following tamoxifen treatment. These results suggest that mutations in the p53 pathway and complete loss of wild-type p53 were not sufficient to allow sustained expansion of \(\text{E\textsubscript{µ}-Myc}\) lymphomas with homozygous \(\text{Mcl-1}\) loss.

Therefore, and since mutations in p53 are a common feature of many human cancers [Vousden and Lane 2007], we investigated whether p53 pathway defects could render Burkitt lymphoma cells resistant to MCL-1 targeting. Mutations of the p53 gene, clustering around “hot spot” residues in the DNA-binding domain that are known to abrogate p53 function [Cho et al. 1994; Petritjean et al. 2007; Freed-Pastor and Prives 2012], were detected in Rael-BL, Sav-BL, and BL-31 and globally in ~60% of the 16 Burkitt lymphoma cell lines tested (note that many lines were in early passage) [Fig. 5C,D]. Importantly, all Burkitt lymphoma cells that retained wild-type p53 genes displayed other abnormalities in the p53 tumor suppressor pathway, including HDM2 overexpression [Fig. 5C] or p14ARF locus deletion [BL2] [Fig. 5D]. Thus, functional inactivation of the p53 tumor suppressor pathway appears to constitute a critical step in the pathogenesis of c-MYC-driven Burkitt lymphoma but is insufficient to overcome the exquisite growth dependency of these malignant cells on MCL-1. Therefore, therapeutic targeting of MCL-1 would still remain an effective treatment regime for Burkitt lymphoma and possibly other c-MYC-driven human cancers.

**Discussion**

Up to 70% of human cancers display deregulated c-MYC overexpression [Boxer and Dang 2001; Sanchez-Beato et al. 2003]. Identifying the cellular factors critical for the growth of c-MYC-driven cancers therefore remains an important objective for designing novel treatment strategies.

We investigated this by using two novel, innovative approaches: conditional deletion of \(\text{Mcl-1}\) or \(\text{Bcl-x}\) genes at will in \(\text{E\textsubscript{µ}-Myc}\) lymphomas within the whole mouse or inducible expression of polypeptides that inhibit specific BCL-2 prosurvival proteins [mimicking the action of drugs that target these proteins, e.g., ABT-737 or ABT-263/nivitoclax] in human Burkitt lymphoma cells. We found that although BCL-X\textsubscript{L} is essential for \(\text{E\textsubscript{µ}-Myc}\)-induced lymphoma development [Kelly et al. 2011], the loss of BCL-X\textsubscript{L} had only a minimal impact on sustained tumor growth. Consistent with this, treatment of \(\text{E\textsubscript{µ}-Myc}\) lymphomas with the BH3 mimic ABT-737, which targets BCL-2, BCL-X\textsubscript{L}, and BCL-W [Oltersdorf et al. 2005; van Delft et al. 2006], does not cause tumor regression [Mason et al. 2008], suggesting that these three prosurvival proteins are dispensable for sustained \(\text{E\textsubscript{µ}-Myc}\) lymphoma growth. In contrast, sustained growth of \(\text{E\textsubscript{µ}-Myc}\) lymphomas was exquisitely dependent on MCL-1. Remarkably, even heterozygous deletion of \(\text{Mcl-1}\) was sufficient to result in complete regression of ~20% of tumors, allowing long-term survival of formerly lymphoma-burdened mice. Strikingly, analysis of the lymphomas that did relapse revealed that ~60% had escaped \(\text{Mcl-1}\) deletion [mostly due to loss of the Cre recombinase]. Indeed, when the animals bearing lymphomas that escaped \(\text{Mcl-1}\textsubscript{fl/fl}\) allele deletion [and had not acquired mutations in p53] were removed from the analysis, nearly 100% survived lymphoma-free long-term (>180 d post-transplant) [Fig. 3E]. Importantly, this translated into the human disease setting, where we found that MCL-1 blockade efficiently killed Burkitt lymphoma cells, with a lesser impact of BCL-X\textsubscript{L} targeting observed in some lines.

An MCL-1 dependency was also detected in AML mouse models and human AML-derived cell lines [Xiang...
Figure 5. Mutations in p53 reduce but do not ablate the dependency of c-MYC-driven mouse and human lymphomas on MCL-1. (A) Immunoblotting to detect stabilized p53 proteins, indicative of a mutant p53 protein, in extracts from 17 $\text{E}_\mu$-Myc,CreERT2;Mcl-1$^{+/+}$ and six $\text{E}_\mu$-Myc,CreERT2;Mcl-1$^{0/0}$ lymphomas. All but two of the samples were extracted from transplanted and tamoxifen-treated lymphomas. The two exceptions were $\text{E}_\mu$-Myc,CreERT2;Mcl-1$^{+/+}$ #9, which was a primary lymphoma, and $\text{E}_\mu$-Myc,CreERT2;Mcl-1$^{0/0}$ #3, which was a transplanted but not tamoxifen-treated lymphoma (this particular lymphoma has the deletion of two bases that introduces a premature stop codon in the p53 gene). Probing for HSP70 served as a loading control. (B) Summary of the p53 mutations detected in $\text{E}_\mu$-Myc,CreERT2;Mcl-1$^{+/+}$ and $\text{E}_\mu$-Myc,CreERT2;Mcl-1$^{0/0}$ lymphomas as detected by DNA sequence analysis. The mutations are listed as wild-type [wt] amino acid (aa) affected, amino acid position, and mutant amino acid. The frequencies at which the mutations were detected in the lymphomas and the human equivalents of the mutations are listed. The sequence alignment for murine p53 was performed using Ensembl transcript number ENSMUST00000108658 as the reference transcript. (C) Immunoblotting to detect the expression of HDM2, p53, and $\beta$-Actin (loading control) in human Burkitt lymphoma cell lines. (D) Summary of the p53 pathway aberrations detected in the human Burkitt lymphoma cell lines. The p53 mutations present in each cell line is listed as wild-type [wt] amino acid [aa] affected, amino acid position, and mutant amino acid, and the number of alleles affected is also detailed.
et al. 2010; Glaser et al. 2012]. This finding and the observation that ~10% of diverse tumors contain somatically acquired amplifications of the genomic region harboring MCL-1 [Beroukhim et al. 2010] highlight the importance of developing BH3 mimetic drugs that selectively target MCL-1 for treating human cancers. A concern is that MCL-1 is required for the survival of hematopoietic stem/progenitor cells [Opferman et al. 2005] and several other critical cell types, including cardiomyocytes [Opferman et al. 2003; Vikstrom et al. 2010; Thomas et al. 2013; Wang et al. 2013]. Importantly, our discovery that MYC-driven lymphomas cannot tolerate even heterozygous loss of Mcl-1 (which should mimic 50% drug-mediated inhibition of the protein), whereas its heterozygous loss is well tolerated in normal tissues [Opferman et al. 2003, 2005; Vikstrom et al. 2010], indicates that it should be possible to establish a therapeutic window for MCL-1 inhibitory drugs.

A novel and highly important finding from this study is the observation that mutations in “hot spot” residues in the DNA-binding domain of the p53 gene can reduce but not abrogate the lymphoma cells’ dependency on MCL-1. Consistent with a recent study that found that p53 mutations are the fourth most commonly detected genetic change in a large panel of Burkitt lymphoma biopsies [Love et al. 2012], we found that ~60% of Burkitt lymphoma lines had acquired mutations in the DNA-binding domain of p53 [Petitjean et al. 2007]. Remarkably, all of the remaining Burkitt lymphoma lines examined displayed some other abnormalities in components of the p53 pathway, such as HDM2 overexpression or p14/ARF loss. Importantly, MCL-1 antagonism was able to kill Burkitt lymphomas with p53 pathway defects, suggesting that MCL-1 inhibitory drugs could be efficacious in the treatment of c-MYC-driven cancers bearing p53 mutations.

The network of processes that p53 activates to suppress tumorigenesis are still emerging [Brady et al. 2011; Li et al. 2012; Valente et al. 2013]. The observation that mutation and loss of p53 constitute critical steps in c-MYC-driven lymphomagenesis [Vousden and Lane 2007; Michalak et al. 2009] and that they can facilitate the sustained growth of malignant Eμ-Myc lymphomas with reduced MCL-1 expression highlights the connection between the p53 tumor suppressor pathway and the dependency of malignant cells on prosurvival MCL-1.

Our results are consistent with a model [Fig. 6] in which c-MYC-driven lymphomas are highly dependent on MCL-1 for survival. A reduction of MCL-1 expression through either genetic means or, in the future, therapeutics could induce cell death by disturbing the balance between the proapoptotic p53 targets PUMA/NOXA and the prosurvival protein. A concern is that MCL-1 inhibitory drugs could be efficacious in the treatment of c-MYC-driven cancers bearing p53 mutations.

Figure 6. A proposed model in which c-MYC-driven lymphoma cells that are highly dependent on MCL-1 for their sustained expansion can no longer survive once MCL-1 expression is reduced and the balance between this prosurvival protein and the p53 proapoptotic targets PUMA/NOXA is disturbed. The c-MYC-driven lymphoma cells that have acquired p53 mutations display an accelerated lymphoma progression. These lymphomas express less PUMA/NOXA, and, consequently, less MCL-1 expression is required to maintain the lymphoma progression. Despite this, we showed that targeting of MCL-1 in lymphomas with p53 mutations was sufficient to result in tumor regression. Note that the mouse protein nomenclature is used.

Materials and methods

Mice

Experiments with mice were conducted according to the guidelines of The Walter and Eliza Hall Institute Animal Ethics Committee. Eμ-Myc transgenic [Adams et al. 1985], Bcl-XΔ[Δ]I [Wagner et al. 2000], Mcl-1<sup>fl/fl</sup> [Vikstrom et al. 2010], Rosa26-CreERT2 [Seibler et al. 2003], and p53<sup><i>−/−</i></sup> [Jacks et al. 1994] gene targeted mice have all been described previously. All mouse strains were on a C57BL/6-Ly5.2<sup>+</sup>/C0 <sup>E</sup>-Myc transgenic (Adams et al. 1985), Mcl-1<sup>fl/fl</sup> (Vikstrom et al. 2010), and Rosa26-CreERT2 gene background. Bcl-x<sup>-/−</sup> mice were generated using a C57BL/6-Ly5.2<sup>+</sup>/C0 Rosa26-CreERT2 transgenic mouse line. Mice were administered tamoxifen (Sigma-Aldrich) in peanut oil/10% ethanol per day (Anastassiadis et al. 2010) for two consecutive days on either days 5 and 6 or days 10 and 11 post-injection of the tumor cells. Transplants in which the matched control untreated mice did not become sick by 28 days post-tumor cell injection were excluded from the analysis.
Graphpad Prism software was used for generating Kaplan-Meier plots and performing statistical analysis (using a log-rank test) to compare the survival of mice injected with lymphoma cells of different genotypes. Graphpad Prism was also used to carry out paired two-tailed t-tests on the death induced in the Burkitt lymphoma cells following dox-inducible expression of the BIMs variants. Specifically, the significance of the extent of cell death induced by BIMs2A [to target MCL-1] expression compared with either inducible expression of BIMs4E [negative control] or BIMsBAD [to target BCL-2, BCL-XL, and BCL-W] was calculated for each of the Burkitt lymphoma cell lines.

**Cell culture**

*Eμ-Myc* mouse lymphoma cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) [Gibco], 50 μM β-mercaptoethanol [Sigma-Aldrich], 100 μM asparagine [Sigma-Aldrich], 100 U/mL penicillin, and 100 mg/mL streptomycin [Gibco] at 37°C and 10% CO₂. OP9 cells were cultured in αMEM [Gibco] supplemented with 20% heat-inactivated FBS, 1 mM glutamine [Gibco], 10 mM Hepes [Gibco], 1 mM sodium pyruvate [Gibco], 50 μM β-mercaptoethanol, 100 U/mL penicillin, and 100 μg/mL streptomycin. Human cell lines were cultured in a humidified incubator at 37°C and 5% CO₂. Virus-producing 293T cells were maintained in DMEM supplemented with 10% FBS. Approximately 6 h prior to transfection, 293T cells were cultured in DME glutamax [Gibco] supplemented with 10% FBS and 25 mM Hepes. Rael-BL, Ramos-BL, Sav-BL, and BL-31 human Burkitt lymphoma-derived cell lines were cultured in RPMI 1640 supplemented with 10% FBS and 25 mM Hepes. Lael-BL, Ramos-BL, Sav-BL, and BL-31 human Burkitt lymphoma-derived cell lines were cultured in RPMI 1640 supplemented with 10% FBS and 1 mM glutamine.

**Lentiviral plasmids and virus production**

The dox-responsive lentiviral vector pFTR3G_pGK3G_GFP was generated by digesting PacI/AseI and cloning the TRE3G_pGK3G_GFP cassette. The TRE3G_pGK3G_GFP cassette was generated by digesting PacI/AscI and cloning the TRE3G_pGK3G_GFP cassette. The dox-responsive lentiviral vector pFTRE3G_pGK3G_GFP was generated by inserting Luciferase2 linked via a T2A marker of the FUGW vector [Lois et al. 2002]. Lentiviral plasmids and virus production

**Inducible expression of BIMs variants in human Burkitt lymphoma cells**

To induce expression of the BIMs variants, cells were cultured in medium supplemented with 1 μg/mL dox. The viability of the GFP-positive cells was determined by propidium iodide (PI) staining and FACS analysis in an LSR1 machine. The PI-negative/GFP-positive cells were considered as live cells. The cell death following inducible expression of the BIMs variant was expressed relative to the untreated Burkitt lymphoma cells, which were assigned a value of 1. For the analysis of the BIMs variant expression by immunoblotting, the pan-caspase inhibitor qVD-OPh [25 μM, MP Biomedicals] was added to the dox-treated cells for 24 h to inhibit cell killing.

**Direct binding assays to determine the binding parameters of BH3 ligands for BCL-Xs and MCL-1**

Direct binding assays were performed at room temperature using a Biacore S1 biosensor exactly as described previously [Lee et al. 2007]. The peptides used were BIMs BH3, DMRPEWIAQELRR IGEDEFNAYYARR, BIMs2A BH3, DMRPEWIAQARRIGDEA NAYYARR, and BADs BH3, NLWAAQRGRELIRMSDFVDS FKKG.

**Immunofluorescent staining, flow cytometric analysis, and cell sorting**

To immunophenotype *Eμ-Myc* lymphomas, single-cell suspensions were stained as described [Strasser et al. 1991] with surface marker-specific antibodies and analyzed using an LSR1 machine [Becton Dickinson]. The following fluorochrome-conjugated antibodies were used: CD19 [clone ID3], B220 [RA3-6B2], IgM [clone 5.1], IgD [clone 11-26C], CD4 [clone H129], CD8 [clone YTS.169], Thy1 [clone T3.24.1], Mac1 [M1/70], and Gr1 [clone RB6-8C5]. To discriminate host-derived [Ly5.1+] from donor-derived [Ly5.2+] cells, monoclonal antibodies to Ly5.1 [clone A201.1] and Ly5.2 [clone 5.450.15.2 or AL14A7] were used. To verify recombination of the *foxo1*-flanked allele of Mcl-1, cells were stained with antibodies to human CD4 [clone RPA-T4], since Mcl-1*Δ* recombination subjugates a human CD4 reporter cassette to the Mcl-1 promoter/enhancer [Vikstrom et al. 2010]. Antibodies were produced in our laboratory and conjugated to FITC, R-phycocerythrin (R-PE), or allophycocyanin (APC) according to the manufacturers’ instructions. Where required, Burkitt lymphoma cells were sorted for GFP expression using an AriaII cell sorter [Becton Dickinson].

**Immunoblotting**

Total protein extracts were prepared from cells [primary *Eμ-Myc* lymphomas and Burkitt lymphoma cell lines] by lysis in onyx buffer, NP40 buffer, or urea buffer containing protease inhibitors [Complete protease inhibitor cocktail, Roche]. Protein content was quantified using the Bio-Rad Bradford assay. Total protein extracts [20 μg] were separated on the basis of molecular weight by SDS-PAGE and Western-blotted onto nitrocellulose membranes. The membranes were blocked in 5% skim milk in PBS and 0.1% Tween20 [blocking buffer] before incubation with antibodies. Polyclonal antibodies were used to detect mouse MCL-1 [Rockland Antibodies and Assays], BIM [Enzo Life Sciences], BCL-x [BD Biosciences], and human MCL-1 [s-19, Santa Cruz Biotechnology]; monoclonal antibodies were used to detect mouse p53 [clone IMX25, Novocastra], p19/ARF [clone 5.C3.1, Rockland Antibodies and Assays], ERα [to detect the CreERT2 protein] [clone HC-20, Santa Cruz Biotechnology],

**Statistical analysis**

Graphpad Prism was used for generating Kaplan-Meier plots and performing statistical analysis (using a log-rank test) to compare the survival of mice injected with lymphoma cells of different genotypes. Graphpad Prism was also used to carry out paired two-tailed t-tests on the death induced in the Burkitt lymphoma cells following dox-inducible expression of the BIMs variants. Specifically, the significance of the extent of cell death induced by BIMs2A [to target MCL-1] expression compared with either inducible expression of BIMs4E [negative control] or BIMsBAD [to target BCL-2, BCL-XL, and BCL-W] was calculated for each of the Burkitt lymphoma cell lines.

**Lentiviral transduction of *Eμ-Myc* lymphoma cells and Burkitt lymphoma cell lines**

For infection, aliquots of 0.5 × 10⁶ to 1 × 10⁶ primary *Eμ-Myc* lymphoma cells or 1 × 10⁶ Burkitt lymphoma cells were suspended in 4 mL of virus-containing supernatant containing 10 ng/mL polybrene, incubated for 30 min at 37°C and 5% or 10% CO₂, and then centrifuged at 2200 rpm for 2.5 h at 32°C. The supernatant was subsequently discarded, and the cells were resuspended in fresh medium for culture.

**MCL-1 is essential for MYC-driven lymphoma growth**
Actin (clone AC40, Sigma-Aldrich), and β-Actin (clone AC74, Sigma-Aldrich), and monoclonal antibodies were used to detect human p53 (clone FL9393), HD2M (clone N20), BCL-2 (clone C-2), BCL-XL (clone H5) [all from Santa Cruz Biotechnology], β-Actin (clone AC15, Sigma-Aldrich), and HSP70 (mouse monoclonal antibody clone N6; detects both mouse and human protein) [a gift from Dr R Anderson, Peter MacCallum Cancer Research Institute, Melbourne, Australia]. All antibodies were diluted in blocking buffer.

qRT–PCR analysis

Total RNA was extracted from paired untreated and tamoxifen-treated Eμ-Myb lymphoma cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The RNA was treated with DNase to remove contaminating DNA using the RNase-free DNase Qiagen kit according to the manufacturer's instructions. RNA quality and quantity were determined using the NanoDrop assay (Thermo Fisher Scientific). Aliquots of 1 μg of RNA were reverse-transcribed into cDNA using the SuperScript III first strand synthesis Supermix kit (Invitrogen) in a 20-μL reaction volume according to the manufacturer's instructions. The cDNA was diluted 10-fold in H₂O, and PCR amplifications of 1 μL of cDNA were performed with an Applied Biosystems 7900HT thermal cycler using TaqMan Universal PCR Mastermix and 0.5 μL of TaqMan primer/probes [both Applied Biosystems] in a 10-μL reaction volume. Assays specific for Bcl-x [Mm00437783] and [as an endogenous control for RNA quality/input] HMBS [Mm01143545] transcripts were performed. Three replicates of each reaction were performed. All qPCR data were analyzed using the 2⁻ΔΔCT method and expressed relative to the untreated sample of each pair.

IVIS imaging

Single-cell suspensions of lymphoma cells taken from the lymph nodes, spleens, or thymuses of sick Eμ-Myb,CreERT2,Bcl-xfl/fl and Eμ-Myb,CreERT2,Mcl-1fl/fl mice were transduced with a GFP-luc lentiviral vector as described above. Transduced cells were cultured for three passages on an OP9 cell feeder layer and imaged using the IVIS live-imaging system (Perkin Elmer) to monitor the total photon flux per second emitted by measuring the total photon flux per second emitted from a region of interest [ROI] drawn around the whole mouse. When the lymphoma burden was sufficiently high ( photon flux per second of >1 × 10⁴), some mice from each cohort were administered tamoxifen by oral gavage once per day for three consecutive days, and the tumor regression/progression was monitored by further bioluminescence imaging at indicated time points.

Human p53 cDNA sequence analysis

The human p53 gene status was determined by sequencing of cDNA [Lindstrom et al. 2001]. Total RNA was extracted from cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The cDNA was made from total RNA using the Advantage one-step RT–PCR kit according to the manufacturer's instructions (Clontech). p53 was sequenced from pooled PCR reactions using the following primers: p53F1 [5'-GA AGGATCCGGAGGCGCATG-3'], p53F81 [5'-CTGAGGTT GGTCTCTGACTCATACCATC-3'], p53R789 [5'-AACCAAG CCTATTACCTGAGGTCTTC-3'], and p53R1179 [5'-AGGG AATCAGTCTGACTCAGG-3'].

DNA extraction, PCR, and DNA sequence analysis

DNA was extracted from cells using the Qiagen DNeasy tissue kit (Qiagen) according to the manufacturer's instructions, and the DNA concentration was quantified using the Nanodrop assay. Exons 4, 5–6, 7, 8–9, and 10 of the mouse p53 gene were PCR-amplified from 100 ng of DNA using GoTaq green master mix [M712, Promega] and 3.3 μM primers using 32 cycles of 1 min at 94°C, 1 min at 52°C, and 1 min at 72°C followed by a 5-min extension at 72°C. DNA sequence analysis was performed by Micromon Monash. The following primer combinations were used to PCR-amplify and sequence mouse p53: Ex4F [5'-GGTT CTTCTTTTTCCATCC-3'] with Ex4R [5'-GAGGGCATTGA AAGGCTCAC-3'], Ex5F [5'-TTAGTTTCCACCTGGTACAC-3'] with Ex6R [5'-AGGGTGAGTTGGAGGAG-3'] and Ex7F [5'- TAGTGAGGTAGGGAGCGACTTC-3'] with Ex8R [5'-CCAG AGGAAACAGAGGAG-3'], Ex8F [5'-CTCTTCGGGGTCTCGTAAAC-3'] with Ex9R [5'-CTCTGGACCTAATGAAC -3'] and Ex10F [5'-AACACTCTAAGTGGAGCCAG-3'] with Ex10R [5'-ATGATCGTTTCTGAGGCTGC-3']. The sequence alignment for murine p53 was performed using Ensembl transcript number ENSMUST00000108658 as the reference transcript.

DNA PCR to detect Mcl-1fl/wt, Mcl-1fl/fl, and recombinant Mcl-1 alleles

The wild-type, Mcl-1fl/fl, and recombinant Mcl-1fl/fl alleles were PCR-amplified from 100 ng of DNA using GoTaq green master mix [M712, Promega] and 0.5 μM primers using 30 cycles of 40 sec at 94°C, 30 sec at 55°C, and 1 min at 72°C followed by a 5-min extension at 72°C. The following primers were used to detect Mcl-1fl and Mcl-1wt alleles: 5'-GGCACAATGCCGTCCGCAGCC AA-3' and reverse 5'-GCGGCGATCCACCCAGTGCTCAG-3'. The wild-type PCR product was smaller than the floxed PCR product. The following primers were used to detect recombinant Mcl-1fl/fl alleles: 5'-GCAGACAGATGACAGGCGCTTC-3' with 5'-GAGCTCGCGAGCTTCAAGC-3'.

DNA PCR to detect homozygous deletion of the CKD2NA (INK4A/ARF) locus

The following PCR primers were used: exon 1F, [F, 5'-TGC AGTTAAAGGCGAGCAGG-3'; R, 5'-TTATCTCTCCCTCTCCT CCTAGCCTG-3']), and exon 2 [551R, 5'-CTGAGGGTCTGGA AGCTCTTC-3'; 42F, 5'-GGAAATGGAAACTGGAAC-3']. A GAPDH exon 8 fragment served as control for integrity of DNA.

Acknowledgments

We thank G. Siciliano and his team for help with animal husbandry, C. McLean for editorial assistance, Dr. J.M. Adams and Dr. S. Cory for advice and discussions, and Dr. Kelly Rogers for help with imaging of mice. This work is supported by a Kay Kendall Leukemia Fund Intermediate Fellowship [KKL331] and an EMBO short-term fellowship [both awarded to G.L.K.]; the National Health and Medical Research Council, Australia [program grant 1016701 and fellowship 1020363 to A.S., project grant APP1049720 to M.J.H., project grant APP1041936 to W.D.E., and career development fellowship APP1024620 to E.F.L.]; Cancer Research UK [program grant awarded to L.F., M. Rowe, and
A.B.R.), the Leukemia Foundation, the Leukemia and Lymphoma Society (specialized center of research 7001-13); and a German Research Council Fellowship (He 5740/1-1 awarded to M.J.H.). This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Research Institutes Infrastructure Support Scheme.

References


Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT.


